Its a valid point , but also you need to look at whats coming...

Its a valid point , but also you need to look at whats coming around the corner, the cost savings just being made are going to be dwarfed by outgoings needed to be made:



The average cost of phase 1, 2, and 3 clinical trials across therapeutic areas is around $4, 13, and 20 million respectively.


AC8 has approx 13 million AUD in the bank, even if you want to go just by the last year to take in your point , losing 1.1 million on average a quarter. AC8 will have about 10 mill in bank next year when they are commencing two trials.

I think its easy to put together what will need to happen for them to go down this path. Thats why Im pretty sure another CR is around the corner, perhaps they will try to do a pump before hand as @xtvu points to.